Relmada Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate. Cash and Equivalents $202.1M.

Benzinga · 2d ago
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 60 percent increase over losses of $(0.30) per share from the same period last year.